The mutant IDH-1 reduces the conversion of α-ketoglutarate to D-2-hydroxyglutarate (D2HG), and the levels of D2HG are known to surpass 30 mM in IDH-1 mutant gliomas (Dang et al., 2009). Here, IDH1 is linked to central nervous system cancer.